Intravenous thrombolysis for acute ischaemic stroke in the setting of rivaroxaban use

Abstract

The risk of thrombolysis in patients taking novel anticoagulants remains unclear. We describe a patient with a large acute ischaemic stroke, who had a low calibrated anti-factor Xa level, who safely received thrombolysis 15-17 hours after standard dose rivaroxaban without subsequent intracerebral haemorrhage.